Preoperative and Postoperative Radiosurgery in Patients With Brain Metastases Undergoing Surgery (PREOPRAD)
Randomized Phase II/III Study Comparing Preoperative Radiosurgery Versus Postoperative Radiosurgery in Patients With Brain Metastases Eligible for Surgery: Correlation With Histopathological Factors and Radiomic Analysis.
The PREOP-RAD study aims to evaluate the feasibility, safety, and efficacy of preoperative surgical resection (SRS) in patients with large brain metastases requiring surgical resection, taking into account potential differences based on sex/gender, compared to postoperative SRS, within the Spanish healthcare context.
More specifically, the study seeks to:
- Assess the clinical and radiological outcomes of the preoperative strategy in terms of local control, progression-free survival, and the occurrence of radionecrosis or neuromuscular dysfunction (nMD) compared to the postoperative strategy.
- Study the histopathological profile of resected lesions before and after SRS, searching for personalized biomarkers of response and toxicity.
- Identify patterns based on radiomic analysis and advanced imaging related to therapeutic response, recurrence, and complications.
PREOP-RAD is a prospective, randomized, multicenter study that will include patients diagnosed with symptomatic, single or multiple brain metastases ≥2 cm who are candidates for surgical resection. The procedure will consist of preoperative administration of SRS (1-5 fractions, depending on location and size), followed by surgery within a maximum of 10 days.
The intervention will be carried out in coordination with the Neurosurgery and Radiation Oncology Departments of each participating center, using a standardized workflow. The collection of surgical samples will allow for centralized histopathological studies. Furthermore, pre- and postoperative images will undergo radiomic analysis using artificial intelligence tools to explore similarities and correlate morphological and textural characteristics with clinical outcomes.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
Preoperative SRS has emerged as a promising alternative. Administered before surgery, it allows for more precise planning, less exposure of healthy tissue, avoids delays due to surgical complications, and reduces the risk of neuromuscular dysfunction (nMD) by eliminating prior tumor manipulation. Recent retrospective studies and meta-analyses show local control rates similar to postoperative SRS, with a lower incidence of radionecrosis (1.5% vs. 14.6%) and nMD (3% vs. 17%). However, most of this data comes from North American centers, and prospective studies evaluating this strategy within the Spanish healthcare system, and especially its differentiated impact on patients by sex, are lacking.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Badajoz
-
Badajoz, Badajoz, Spanje, 06080
- Nog niet aan het werven
- Hospital Universitario de Badajoz
-
Contact:
- Victoria Vera Barragán, MD
- Telefoonnummer: +34924 21 81 00
- E-mail: victoria.vera@salud-juntaex.es
-
-
Galicia
-
Vigo, Galicia, Spanje, 36214
- Nog niet aan het werven
- Hospital do Meixoeiro
-
Contact:
- Beatriz Vazquez Barreiro, MD
- Telefoonnummer: +34 986 81 11 11
- E-mail: Beatriz.vazquez.barreiro@sergas.es
-
-
Madrid
-
Madrid, Madrid, Spanje, 28034
- Werving
- Hospital Universitario Ramón y Cajal
-
Contact:
- Eva Lizarbe Fernández, MD
- Telefoonnummer: +3491 336 82 22
- E-mail: eva.lizarbe@gmail.com
-
Madrid, Madrid, Spanje, 28034
- Nog niet aan het werven
- Hospital Ruber Internacional
-
Contact:
- Rafael Garcia Garcia, MD
- Telefoonnummer: +34913 87 50 00
- E-mail: rafael.garciag.ce@ruberinternacional.es
-
-
Navarre
-
Pamplona, Navarre, Spanje, 31008
- Werving
- Hospital Universitario de Navarra
-
Contact:
- Paola Anna Jablonska, MD
- Telefoonnummer: +34848 428 482
- E-mail: paolajablonska@gmail.com
-
Contact:
- Cristina Gutierrez, PhD
- Telefoonnummer: +34848433454
- E-mail: cristina.gutierrez.povedano@navarra.es
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age ≥18 years.
- Histologically confirmed solid tumor with one to four brain metastases.
- At least one brain metastasis considered suitable for surgical resection and stereotactic radiosurgery.
- Karnofsky Performance Status (KPS) ≥70.
- Life expectancy ≥3 months.
- Ability to undergo MRI examinations.
- Written informed consent provided.
Exclusion Criteria:
- Brain metastases from small-cell lung cancer, germ cell tumors, lymphoma, or leukemia.
- Prior radiotherapy to the index lesion.
- Leptomeningeal disease at baseline.
- Contraindication to surgery or stereotactic radiosurgery.
- Pregnancy or breastfeeding.
- Any condition that, in the investigator's opinion, would interfere with study participation or evaluation.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: preoperative radiosurgery
preoperative radiosurgery (SRS) in patients with brain metastases who are candidates for surgery |
radiosurgery (SRS) in patients with brain metastases who are candidates for surgery
Andere namen:
Microsurgical resection of the target brain metastasis, performed either after preoperative SRS or before postoperative SRS depending on treatment arm |
|
Ander: postoperative radiosurgery
standard treatment, consisting of surgical resection followed by irradiation of the tumor bed |
radiosurgery (SRS) in patients with brain metastases who are candidates for surgery
Andere namen:
Microsurgical resection of the target brain metastasis, performed either after preoperative SRS or before postoperative SRS depending on treatment arm |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Locoregional adverse event-free survival
Tijdsspanne: From randomization to the first locoregional adverse event, assessed up to 12 months after randomization
|
A side effect or complication occurring specifically in the region or site where a medical procedure or treatment-such as surgery or radiotherapy-was performed. |
From randomization to the first locoregional adverse event, assessed up to 12 months after randomization
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Meningeal Failure Rate
Tijdsspanne: 6 and 12 months after randomization.
|
Proportion of patients developing nodular meningeal disease (nMD) during follow-up, as determined by clinical assessment and brain magnetic resonance imaging (MRI). |
6 and 12 months after randomization.
|
|
Symptomatic Radiation Necrosis Rate
Tijdsspanne: 6 and 12 months after randomization.
|
Proportion of patients developing symptomatic radiation necrosis confirmed by clinical and radiological evaluation. |
6 and 12 months after randomization.
|
|
Local Control Rate
Tijdsspanne: 6 and 12 months after randomization.
|
Proportion of patients without local recurrence at the treated lesion or surgical cavity, as assessed by brain MRI. |
6 and 12 months after randomization.
|
|
Distant Brain Failure-Free Survival
Tijdsspanne: 6 and 12 months after randomization.
|
Time from randomization to the occurrence of distant intracranial failure, defined as the appearance of new brain metastases outside the treated lesion(s). |
6 and 12 months after randomization.
|
|
Overall Survival
Tijdsspanne: 6 and 12 months after randomization.
|
Time from randomization to death from any cause. |
6 and 12 months after randomization.
|
Andere uitkomstmaten
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time to Whole-Brain Radiotherapy (WBRT)
Tijdsspanne: From randomization until administration of WBRT, up to 42 months.
|
Time from randomization to the administration of whole-brain radiotherapy (WBRT). |
From randomization until administration of WBRT, up to 42 months.
|
|
Health-Related Quality of Life
Tijdsspanne: Baseline, and at 3, 6, 12, 18, and 24 months after treatment.
|
Change from baseline in health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Brain Neoplasm 20 (EORTC QLQ-BN20). The questionnaire includes 20 items organized into 4 disease-specific symptom scales (future uncertainty, visual disorder, motor dysfunction, communication deficit) and 7 single items. All scores are linearly transformed to a scale from 0 to 100, where a higher score represents a higher level of symptoms or worse outcome (greater symptom burden). |
Baseline, and at 3, 6, 12, 18, and 24 months after treatment.
|
|
Length of Hospital Stay
Tijdsspanne: From the date of admission for the surgical procedure until the date of hospital discharge, assessed up to 30 days.
|
Duration of hospital stay measured in days, defined as the time from the date of hospital admission for the surgical procedure until the date of hospital discharge. |
From the date of admission for the surgical procedure until the date of hospital discharge, assessed up to 30 days.
|
|
Treatment Delay
Tijdsspanne: From treatment planning to treatment completion, up to 42 months.
|
Time elapsed between the protocol-defined optimal treatment schedule and the actual administration of treatment. |
From treatment planning to treatment completion, up to 42 months.
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Pathologische processen
- Neoplasmata per site
- Neoplasmata
- Neoplastische processen
- Neoplasmata van het zenuwstelsel
- Neoplasmata van het centrale zenuwstelsel
- Pathologische aandoeningen, tekenen en symptomen
- Neoplasma metastase
- Hersenneoplasmata
- Onderzoekstechnieken
- Therapeutica
- Chirurgische procedures, operatief
- Radiotherapie
- Stereotaxische technieken
- Neurochirurgische procedures
- Radiochirurgie
Andere studie-ID-nummers
Andere studie-ID-nummers
- PREOPRAD
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .